Brought to you by 
Kepivance, Stemgen, & Kineret deal for Amgen, Biovitrum
20 Jan 2017
Executive Summary
Biovitrum AB has outright acquired Kepivance (palifermin) and Stemgen (ancestim) from Amgen as well as gained an exclusive global license to Amgen's Kineret (anakinra). Biovitrum has purchased an inventory of the three products.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- Product Purchase
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kepivance, Stemgen, & Kineret deal for Amgen, Biovitrum
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice